Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.34 HKD | +2.69% | +10.10% | -29.83% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 11 for the current year and 9.15 for next year, earnings multiples are highly attractive compared with competitors.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.83% | 3.12B | B- | ||
+9.17% | 27.27B | B+ | ||
-15.97% | 2.53B | C+ | ||
+18.11% | 2.47B | - | A- | |
+3.70% | 2B | B | ||
-9.47% | 1.91B | - | ||
-2.22% | 1.48B | B | ||
+2.78% | 1.3B | - | ||
+18.92% | 1.18B | C | ||
+3.72% | 1.13B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1066 Stock
- Ratings Shandong Weigao Group Medical Polymer Company Limited